Amgen "buy"

19.12.07 - Deutsche Securities

NEW YORK, December 19 (newratings.com) - Analysts at Deutsche Bank Securities maintain their "buy" rating on Amgen Inc (AMGN). The target price is set to $70.

In a research note published yesterday, the analysts mention that the company has presented positive Phase III results for D-mab in tx induced bone loss in non-metastatic breast cancer. Amgen?s share price is expected to come under pressure going into 1Q08, especially around the time of the ODAC review of Aranesp and recent off-label studies that suggest a potential increase in safety concerns, Deutsche Bank Securities adds.